The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.
Open accessAbstract
Epidermal growth factor (EGF) at 3 nM maximally inhibits the proliferation of A431 epidermoid carcinoma cells. We show that at lower concentrations, in the range of 3-100 pM, EGF has a mitogenic effect on A431 cells. In the presence of 100 nM anti-EGF-receptor monoclonal IgG (designated 528), which inhibits A431 cell proliferation and blocks greater than 95% of EGF binding, EGF becomes mitogenic for A431 cells at concentrations up to 3 nM. These results suggest that a minor population of high-affinity EGF receptors may be involved in stimulation of A431 cell proliferation. Saturation binding assays with 125I-labeled EGF indicate that approximately equal to 0.1-0.2% of receptors for EGF are high-affinity receptors that bind EGF with an estimated Kd of 7 X 10(-11) M. This affinity is nearly 2 orders of magnitude higher than that of the remaining EGF receptors. Although A431 cell proliferation is maximally inhibited by nonsaturating amounts of EGF (3 nM), maximal inhibition by 528 IgG (approximately equal to 70% of maximal inhibition by EGF) requires saturating concentrations of antibody (approximately equal to 15 nM). Unlike EGF, rapid down-regulation is not observed with 528 IgG. These results indicate different mechanisms of growth inhibition of A431 cells by EGF and 528 IgG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity
HUNTER, W. M., & GREENWOOD, F. C. (1962) · Nature · doi:10.1038/194495a0 · Cited by 6,919
Carpenter, G., & Cohen, S. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001205 · Cited by 2,909
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Coated pits, coated vesicles, and receptor-mediated endocytosis
Goldstein, J. L., Anderson, R. G. W., & Brown, M. S. (1979) · Nature · doi:10.1038/279679a0 · Cited by 1,532
Methods for growth of cultured cells in serum-free medium
Barnes, D., & Sato, G. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90151-7 · Cited by 1,002
Self-citationDansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells.
Haigler, H. T., Maxfield, F. R., Willingham, M. C., & Pastan, I. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86019-2 · Cited by 792
Nerve growth factor receptors on human melanoma cells in culture.
Fabricant, R. N., De Larco, J. E., & Todaro, G. J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.2.565 · Cited by 657
Haigler, H., Ash, J. F., Singer, S. J., & Cohen, S. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.7.3317 · Cited by 568
Haigler, H. T., McKanna, J. A., & Cohen, S. (1979) · The Journal of cell biology · doi:10.1083/jcb.81.2.382 · Cited by 526
Shoyab, M., De Larco, J. E., & Todaro, G. J. (1979) · Nature · doi:10.1038/279387a0 · Cited by 504
Cited by
Genistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Autocrine growth factors and cancer
Sporn, M. B., & Roberts, A. B. (1985) · Nature · doi:10.1038/313745a0 · Cited by 1,438
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Self-citationThe discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
“A visionary effort and landmark accomplishment in EGFR-targeted cancer therapy was the design of the mouse mAbs 225 and 528 to extracellular epitopes of the recepto”
BackgroundStructural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Jänne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,052
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Self-citationCritical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Robb, R. J., Greene, W. C., & Rusk, C. M. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1126 · Cited by 725
Cochet, C., Gill, G. N., Meisenhelder, J., Cooper, J. A., & Hunter, T. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43389-8 · Cited by 711
Bremer, E. G., Schlessinger, J., & Hakomori, S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35954-9 · Cited by 706
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citationUnderstanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., & Yarden, Y. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00356.x · Cited by 674
Huang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595
Au–Fe3O4 Dumbbell Nanoparticles as Dual‐Functional Probes
Xu, C., Xie, J., Ho, D., Wang, C., Kohler, N., Walsh, E. G., Morgan, J. R., Chin, Y. E., & Sun, S. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200704392 · Cited by 526
Smart drugs: Tyrosine kinase inhibitors in cancer therapy
Shawver, L. K., Slamon, D., & Ullrich, A. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00039-9 · Cited by 522
Yarden, Y., & Schlessinger, J. (1987) · Biochemistry · doi:10.1021/bi00379a034 · Cited by 507
Monodisperse Magnetic Nanoparticles for Theranostic Applications
Ho, D., Sun, X., & Sun, S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200090c · Cited by 504
Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., & Beger, H. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116001 · Cited by 492
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Impact of EGFR expression on colorectal cancer patient prognosis and survival
Spano, J.-P., Lagorce, C., Atlan, D., Milano, G., Domont, J., Benamouzig, R., Attar, A., Benichou, J., Martin, A., Morere, J.-F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi006 · Cited by 462
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Self-citationHerbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Busam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04226.x · Cited by 419
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Self-citationHerbst, R. S., Arquette, M., Shin, D. M., Dicke, K., Vokes, E. E., Azarnia, N., Hong, W. K., & Kies, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.120 · Cited by 402
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Molecular targets of glioma invasion
Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., & Berens, M. E. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6342-5 · Cited by 387
Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment
Grunwald, V., & Hidalgo, M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.12.851 · Cited by 383
Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382
A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
Gustavsson, B., Carlsson, G., Machover, D., Petrelli, N., Roth, A., Schmoll, H.-J., Tveit, K.-M., & Gibson, F. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.11.002 · Cited by 381
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
Self-citationMendez, M. J., Green, L. L., Corvalan, J. R. F., Jia, X.-C., Maynard-Currie, C. E., Yang, X.-D., Gallo, M. L., Louie, D. M., Lee, D. V., Erickson, K. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-146 · Cited by 376
Intermolecular association of the p185 protein and EGF receptor modulates EGF receptor function
Wada, T., Qian, X., & Greene, M. I. (1990) · Cell · doi:10.1016/0092-8674(90)90697-d · Cited by 361
Chen, W. S., Lazar, C. S., Lund, K. A., Welsh, J. B., Chang, C.-P., Walton, G. M., Der, C. J., Wiley, H. S., Gill, G. N., & Rosenfeld, M. G. (1989) · Cell · doi:10.1016/0092-8674(89)90867-2 · Cited by 350
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn, J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080003 · Cited by 330
Self-citationLu, Z., Jiang, G., Blume-Jensen, P., & Hunter, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4016-4031.2001 · Cited by 329
Iwashita, S., & Fox, C. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43390-4 · Cited by 326
Recent Progress in Syntheses and Applications of Dumbbell‐like Nanoparticles
Wang, C., Xu, C., Zeng, H., & Sun, S. (2009) · Advanced Materials · doi:10.1002/adma.200900320 · Cited by 318
Pfister, D. G., Su, Y. B., Kraus, D. H., Wolden, S. L., Lis, E., Aliff, T. B., Zahalsky, A. J., Lake, S., Needle, M. N., Shaha, A. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1792 · Cited by 297
Beguinot, L., Lyall, R. M., Willingham, M. C., & Pastan, I. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.8.2384 · Cited by 290
Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G., & Gill, G. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99131-3 · Cited by 287
Fan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Self-citationDirect Interaction of a Ligand for the erb B2 Oncogene Product with the EGF Receptor and p185 erb B2
Lupu, R., Colomer, R., Zugmaier, G., Sarup, J., Shepard, M., Slamon, D., & Lippman, M. E. (1990) · Science · doi:10.1126/science.2218496 · Cited by 277
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
MacDiarmid, J. A., Amaro-Mugridge, N. B., Madrid-Weiss, J., Sedliarou, I., Wetzel, S., Kochar, K., Brahmbhatt, V. N., Phillips, L., Pattison, S. T., Petti, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1547 · Cited by 272
Santini, J., Formento, J., Francoual, M., Milano, G., Schneider, M., Dassonville, O., & Demard, F. (1991) · Head & Neck · doi:10.1002/hed.2880130209 · Cited by 254
Huang, S.-M., & Harari, P. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006384521198 · Cited by 253
Asano, R., Sone, Y., Makabe, K., Tsumoto, K., Hayashi, H., Katayose, Y., Unno, M., Kudo, T., & Kumagai, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0059 · Cited by 72
Amessou, M., Ebrahim, A. S., Dilly, A., Joseph, M., Tabolina, M., Chukkapalli, S., Meroueh, L., Syed, J. T., Liddane, A., Lang, S. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13008 · Cited by 5
(2001) · PubMed
Metadata
- Authors
- Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1983-03
- Volume
- 80
- Issue
- 5
- Pages
- 1337-1341
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2049613194
- Cited by
- 791
- References
- 25
- FWCI
- 18.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.